Chaitali Nangia, MD, Patty and George Hoag Cancer Center

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.